Table S1. Percentage of cumulative release of AUR from dextran@AUR-coated MNPs at different release media and time intervals

Time (hr)	Percentage of cumulative release (pH= 7.4)					Percentage of cumulative release (pH= 5.5)				
	Sample 1	Sample 2	Sample 3	Average	Standard deviation	Sample 1	Sample 2	Sample 3	Average	Standard deviation
0	1.445	1.217	1.113	1.259	0.170	1.357	1.607	1.670	1.545	0.165
0.5	2.959	2.378	3.125	2.821	0.392	4.088	3.838	4.276	4.068	0.220
1	2.503	3.291	3.042	2.945	0.403	5.235	4.047	4.193	4.492	0.648
3	5.468	4.639	5.697	5.268	0.556	15.285	16.640	18.725	16.884	1.733
6	12.623	14.386	12.457	13.155	1.069	28.004	23.854	26.628	26.162	2.113
9	17.144	15.734	19.259	17.379	1.774	34.863	34.259	37.011	35.378	1.446
12	22.515	21.499	21.727	21.914	0.533	43.078	38.804	41.556	41.146	2.166
24	30.706	25.149	29.69	28.515	2.959	52.628	47.853	49.980	50.153	2.392
48	40.764	36.078	37.363	38.068	2.422	59.571	57.569	61.843	59.661	2.138
72	46.986	42.817	45.866	45.223	2.157	63.094	60.697	65.450	63.080	2.377
96	49.308	45.036	48.914	47.753	2.361	69.912	62.886	66.764	66.521	3.519
120	50.594	47.152	50.013	49.253	1.843	68.891	65.805	69.120	67.938	1.851

Table S2. Two-way ANOVA analyses for assessing the difference in the cytotoxicity effect of dextran@AUR-coated MNPs in comparison to auraptene (AUR) and dextran@Fe$_3$O$_4$ MNPs for PC3, DU145 and LNCaP cell lines. Significance of difference is demonstrated as $P < 0.05$, $P < 0.01$, and $P < 0.001$

Final AUR concentration (µg/mL)	Cell line	Dextran@AUR-coated MNPs vs dextran@Fe$_3$O$_4$ MNPs	Dextran@AUR-coated MNPs vs AUR
	PC3	p>0.05	p>0.05
0.1	DU145	p>0.05	p>0.05
	LNCaP	p>0.05	p>0.05
	PC3	p>0.05	p>0.05
1	DU145	p>0.05	p>0.05
	LNCaP	p>0.05	p>0.05
	PC3	p>0.05	p>0.05
5	DU145	p>0.05	p>0.05
	LNCaP	p<0.001	p<0.001
	PC3	p<0.01	p<0.01
10	DU145	p<0.001	p<0.001
	LNCaP	p<0.001	p<0.001